Intellectual property-based business IP Group reported on Wednesday that Microbiotica, one of its many portfolio companies, has entered into $534m multi-year strategic collaboration deal with Roche Group subsidiary Genentech.
Paragon: Numis upgrades to buy with a target price of 452p.
Intellectual property-based business developer IP Group announced on Friday that Mike Humphrey has indicated that, for personal reasons, he wishes to retire and step down from his position as non-executive chairman and a director of the company, as soon as a suitable replacement can be recruited.
IP Group said on Thursday that its portfolio company, Enterprise Therapeutics, has announced a £29m fundraising.
IP Group swung to a positive return on assets last year as portfolio gains increased at the investor in intellectual property businesses.
Biotech firm Oxford Nanopore has raised £100m from its latest private funding round, valuing the rapidly-expanding UK group somewhere in the vicinity of £1.5bn as a result.
Autifony Therapeutics, a spin-out from GlaxoSmithKline backed by IP Group, has signed a 627.5m central nervous system collaboration with German drugs giant Boehringer Ingelheim.
Mirriad Advertising, a video technology company backed by IP Group plans to float on London's AIM with a £26.2m fundraising to speed its expansion.
IP Group updated the market again on its takeover offer for Touchstone Innovations on Wednesday, confirming that as at 1300 BST on Tuesday, it had received valid acceptances of its offer in respect of 155,859,312 Touchstone shares, representing 96.6844% of Touchstone's issued share capital.
IP Group's offer for Touchstone Innovations was back on track on Tuesday morning, following a statement from the Competition and Markets Authority confirming that the competition watchdog had decided not to refer the merger to a Phase 2 investigation.
IP Group updated the market on its takeover offer for Touchstone Innovations on Monday, confirming an extension to its offer deadline, and confirming it has received support for the offer from shareholders representing more than 97% of Touchstone shares in issue.
Intellectual property-based business IP Group noted on Wednesday morning that Istesso, formerly Modern Biosciences, has announced new data from a cohort of patients dosed as part of a phase 1 study of MBS2320, its investigational drug for the treatment of rheumatoid arthritis.
IP Group announced on Tuesday that its majority owned subsidiary Istesso had completed a successful first round of dosing in a Phase 2a study of a potential rheumatoid arthritis drug.
IP Group said a proposed capital raising in China had been hit by new regulatory controls in the People's Republic.
Intellectual property-business IP Group said on Friday that its portfolio company, Tissue Regenix, has raised £40m through a placing and subscription of new ordinary shares as it announced the acquisition of CellRight Technologies.
Intellectual property-based business developer IP Group saw its net assets grow to £968.1m in its first half, it reported on Tuesday, from £748.5m year-on-year, while its hard net asset value was firmer at £890.5m, from £683.5m 12 months earlier.
Intellectual property-based business IP Group noted on Monday that its portfolio company, Creavo Medical Technologies, had completed a fundraising of £13.4m.
David Newlands, chairman of the board at Touchstone Innovations, wrote to shareholders on Thursday outlining a number of concerns over a recent approach from IP Group to combine the two businesses.
Touchstone Innovations on Tuesday confirmed IP Group's merger approach, adding that it had advised shareholders to take no action.
Intellectual property-based business developer IP Group said it had made an offer for Touchstone Innovations and was also planning to raise £200m in a cash call.